Recent advances in aerosol therapy for children with asthma

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 1, 2006, Pages 61-66

  Devadason, Sunalene G ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Aerosol devices; Drug delivery; Pediatric asthma therapy

Indexed keywords

ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; DEOXYRIBONUCLEASE; FLUTICASONE PROPIONATE; SALBUTAMOL;

ADOLESCENT; AEROSOL; AGE; ASTHMA; BREATHING; CHILD; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DOSE CALCULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRY POWDER; FACE MASK; HUMAN; INFANT; INSPIRATORY CAPACITY; LUNG; LUNG FIBROSIS; METERED DOSE INHALER; NEBULIZER; OROPHARYNX; PATIENT COMPLIANCE; PEDIATRICS; REVIEW; SYSTEMIC DISEASE; TIDAL VOLUME;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; HUMANS; METERED DOSE INHALERS; POWDERS;

EID: 33645461792     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.61     Document Type: Review

References (51)

1. Belvisi, M.G., and D.J. Hele. 2003. Soft steroids: a new approach to the treatment of inflammatory airways disease. Pulmon. Pharmacol. Ther. 16:321-325.
2. Patton, J.S., J.G. Bukar, and M.A. Eldon. 2004. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 43:781-801.
3. Wright, A.L., and L.M. Taussig. 1998. Lessons from long-term cohort studies. Childhood asthma. Eur. Respir. J. 27:17s-22s.
4. Lipworth, B.J., and D.J. Clark. 1998. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer. Br. J. Clin. Pharmacol. 45:160-163.
5. Chou, K.J., S.J. Cunningham, and E.F. Crain. 1995. Metered-dose inhalers with spacers vs. nebulizers for pediatric asthma. Arch. Pediatr. Adolesc. Med. 149:201-205.
6. Castro-Rodriguez, J.A., and G.J. Rodrigo. 2004. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J. Pediatr. 145:172-177.
7. Closa, R.M., J.M. Ceballos, A. Gomez-Papi, et al. 1998. Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing. Pediatr. Pulmonol. 26:344-348.
8. Barry, P.W., and C. O'Callaghan. 1995. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br. J. Clin. Pharmacol. 40:76-78.
9. Wildhaber, J.H., S.G. Devadason, E. Eber, et al. 1996. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 51:985-988.
10. Bisgaard, H., J. Anhoj, B. Klug, et al. 1995. A non-electrostatic spacer for aerosol delivery. Arch. Dis. Child. 73:226-230.
11. Newman, S.P., A.W. Weisz, N. Talaee, et al. 1991. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46:712-716.
12. Devadason, S.G., T. Huang, S. Walker, et al. 2003. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur. Respir. J. 21:1007-1011.
13. Kamin, W.E., T. Genz, S. Roeder, et al. 2002. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol Med. 15:65-73.
14. Bisgaard, H. 1998. Automatic actuation of a dry powder inhaler into a nonelectrostatic spacer. Am. J. Respir. Crit. Care Med. 157:518-521.
15. Chua, H.L., G.G. Collis, A.M. Newbury, et al. 1994. The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. 7:2185-2191.
16. Everard, M.L., J.G. Hardy, and A.D. Milner. 1993. Comparison of nebulized aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 48:1045-1046.
17. Amirav, I., and M.T. Newhouse. 2001. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 108: 389-394.
18. Sangwan, S., B.K. Gurses, and G.G. Smaldone. 2004. Facemasks and facial deposition of aerosols. Pediatr. Pulmonol. 37:447-452.
19. Collis, G.G., H.C. Cole, and P.N. Le Souëf. 1990. Dilution of nebulizer aerosols by air entrainment in children. Lancet 336:341-343.
20. Everard, M.L., A.R. Clark, and A.D. Milner. 1992. Drug deliery from holding chambers with attached face mask. Arch. Dis. Child. 67:580-585.
21. Barry, P.W., and C. O'Callaghan. 1996. The effect of breathing pattern on the clearance of aerosol from spacers. Eur. Respir. J. 9:432s.
22. O'Callaghan, C., J. Lynch, M. Cant, et al. 1993. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax 48:603-606.
23. Kamps, A.W.A., P.L.P. Brand, and R.J. Roorda. 2004. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr. Pulmonol. 37:65-70.
24. Seddon, P.C., and D.P. Heaf. 1990. How well do children use dry powder inhalers? Thorax 45:818.
25. Bentur, L., Y. Mansour, Y. Hamzani, et al. 2004. Measurement of inspiratory flow in children with acute asthma. Pediatr. Pulmonol. 38:204-207.
26. Giraud, V., and N. Roche. 2002. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. 19:246-251.
27. Kamps, A.W.A., B. van Ewjik, R.J. Roorda, et al. 2000. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 29:39.
28. Marguet, C., L. Couderc, P. Le Roux, et al. 2001. Inhalation treatment: errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children. Pediatr. Allergy Immunol. 12:224-230.
29. Le Souef, P.N. 2002. Drug delivery. Med. J. Aust. 177:S69-S71.
30. Smith, N.A., J.P. Seale, and S. Shaw. 1984. Medication compliance in children with asthma. Aust. Paediatr. J. 20:47-50.
31. Gibson, N.A., A.E. Ferguson, T.C. Aitchison, et al. 1995. Compliance with inhaled asthma medication in preschool children. Thorax 50:1274-1279.
32. Dekker, F.W., F.E. Dieleman, A.A. Kaptein, et al. 1993. Compliance with pulmonary medication in general practice. Eur. Respir. J. 6:886-890.
33. Rand, C.S., and R.A. Wise. 1994. Measuring adherence to asthma medication regimens. AM. J. Respir. Crit. Care Med. 149:569-576.
34. Celano, M., R.J. Geller, K.M. Phillips, et al. 1998. Treatment adherence among low-income children with asthma. J. Paediatr. Psychol. 23:345-349.
35. Janssens, H.M., E.M. Heijnen, V.M. de Jong, et al. 2000. Aerosol delivery from spacers in wheezy infants: A daily life study. Eur. Respir. J. 16:850-856.
36. Chaney, G., B. Clements, L. Laudau, et al. 2004. A new asthma spacer device to improve compliance in children: a pilot study. Respirology 9:499-506.
37. Watt, P.M., B. Clements, S.G. Devadason, et al. 2003. Funhaler spacer: improving adherence without compromising delivery. Arch. Dis. Child. 88:579-581.
38. Leach, C.L., P.J., Davidson, and R.J. Boudreau. 1998. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 12:1346-1353.
39. Leach, C.L., P.J. Davidson, T.S. Bredow, et al. 1998. Breath-activated MDI provides optimal lung deposition of HFA-beclomethasone compared with press & breathe metered dose inhaler in asthmatic patients. Am. J. Respir. Crit. Care Med. 157:A637.
40. Conway, J.H., P. Walker, G. Perkins, et al. 1999. Lung deposition characteristics of HFA-134a beclomethasone dipropionate delivered via an Autohaler. Eur. Respir. J. 14:1965.
41. Dolovich, M., R. Rhem, L. Gerrard, et al. 2002. Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma. Am. J. Respir. Crit. Care Med. 161:A33.
42. Vanden Burgt, J.A., W.W. Busse, R.J. Martin, et al. 2000. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J. Allergy Clin. Immunol. 106:1209-1226.
43. Kelly, H.W. 1998. Establishing a therapeutic index for the inhaled corticosteroids. Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J. Allergy Clin. Immunol. 102:S36-S51.
44. Fukushima, C., H. Matsuse, S. Tomari, et al. 2003. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann. Allergy Asthma Immunol. 90:646-651.
45. Todd, G., C. Acerini, R. Ross-Russell, et al. 2002. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch. Dis. Child. 87:457-461.
46. Todd, G.R., C.L. Acerini, J.J. Buck, et al. 2002. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur. Respir. J. 19:1207-1209.
47. Macdessi, J.S., T.L. Randell, K.C. Donaghue, et al. 2003. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. MJA 178: 214-216.
48. Szefler, S.J. 1999. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J. Allergy Clin. Immunol. 104:175-183.
49. Stoeck, M., R. Riedel, G. Hochhaus, et al. 2004. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharmacol. Exp. Ther. 309: 249-258.
50. Lipworth, B.J., M.A. Kaliner, C.F. LaForce, et al. 2005. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann. Allergy Asthma Immunol. 94:465-472.
51. Agertoft, L., and S. Pedersen. 2005. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J. Allergy Clin. Immunol. 115:940-945.